Prescribing information

 

Please note: The resources on this page are for use by HCPs from Great Britain. If HCPs from Northern Ireland would like to request copies of these materials, please contact your Novartis Representative or use the Contact Us form on this site.

 

Below are a selection of resources to help you and your patients stay on track with PIQRAY® + fulvestrant.

 

Piqray Resources for Healthcare Professionals

 

Screenshot from the video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar + Mekinist

THERAPY MANAGEMENT GUIDE

A brochure to provide guidance on the management of specific adverse events that your patients on PIQRAY® + fulvestrant may experience, and how to optimise treatment with appropriate medical management.

Download a digital copy

Screenshot from the video: Dr Paul Nathan discusses the COMBI-AD trial

JOURNAL REPRINTS

For relevant journal publications, including a SOLAR-1 study reprint, please contact Novartis.

Download a digital copy

 

MOA VIDEO

A video depicting the mechanism of action for PIQRAY® against the PIK3CA mutation in HR+/HER2– advanced breast cancer.

 

 

Piqray Resources for Patients

 

Preview of 'Your guide to managing pyrexia'

PATIENT MANAGEMENT GUIDE

A booklet for you to share with your patients, to help them understand more about the treatment they have been prescribed.

Download a digital copy  Request a hard copy  

""

PATIENT SUPPORT WEBSITE

A website for patients who have been prescribed this medicine, to allow them to find out more about their treatment with PIQRAY® plus fulvestrant, such as how it works and the side effects they might experience. Please visit www.illuminatingabc.co.uk and use the password: [email protected]

Access the patient website (HCPs only)

 

As the site grows, we will be adding lots of new content. SIGN UP to receive our email communications and make sure you don’t miss the latest updates.

Rate this content: 
No votes yet
UK | June 2021 | 134780
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]